← All indications
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
Drugs by status
Approved for this indication (8)
Phase 4 trials (4)
Phase 3 trials (36)
- mitoxantrone
- n-acetyl-s-(1,2-dichlorovinyl)-l-cysteine
- azd5305
- tasquinimod
- cabozantinib
- leuprolide
- melphalan
- fludrocortisone
- mgc018
- rucaparib
- sabizabulin
- Ga 68 PSMA-11
- sargramostim
- dexamethasone
- sodium chloride
- jnj-78278343
- custirsen
- deuterated enzalutamide
- carboplatin
- niraparib
- fluzoparib
- cabazitaxel
- pnt2002
- pf-06821497
- 177lu-dota-tlx591
- goserelin
- masitinib
- cc-94676
- 225ac-psma
- denosumab
- +6 more
Phase 2 trials (215)
- escitalopram
- sertraline
- tislelizumab
- bempegaldesleukin
- histrelin
- omeprazole
- venlafaxine
- Tinengotinib
- kx2-391
- azd4635
- fluorouracil
- 99mtc mdp
- tqb3201
- jab-8263
- cediranib
- Alobresib
- sapanisertib
- plx2853
- bevacizumab
- bintrafusp alfa
- afatinib
- cep-11981
- coenzyme a
- nuv-868
- fludarabine
- 177lu-psma-r2
- trastuzumab
- ifinatamab deruxtecan
- toripalimab
- ephb4-hsa fusion protein
- +185 more
Phase 1 trials (152)
- poly-iclc
- crizotinib
- jnj-67856633
- apg-5918
- cx 5461
- jnj-64264681
- birabresib
- anti-psma car nk cells
- oryza sativa
- human choriogonadotropin alfa
- jnj-64619178
- 64cu-dota-daratumumab
- guadecitabine
- sxl01
- ds9051b
- ac176
- vistusertib
- bay 2315497
- vemurafenib
- bms-986460
- fexofenadine
- ponatinib
- tacrolimus
- vitamin k
- imu-935
- azd-5672
- pt-112
- cellgram-dc-pc
- panobinostat
- gt-220f
- +122 more
Other trials (4)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (9)
Organization Involved with Phase 1 Indications (13)